<DOC>
	<DOCNO>NCT02711202</DOCNO>
	<brief_summary>The aim study evaluate efficacy new immunosuppressive protocol base two application anti-CD52 MabCampath ( Alemtuzumab ) single dose anti-TNF-α Remicade ( infliximab ) monoclonal antibody early posttransplant period follow either monotherapy base tacrolimus sirolimus .</brief_summary>
	<brief_title>Sequential Targeting Cluster Differentiation 52 ( CD52 ) Tumor Necrosis Factor ( TNF ) Allows Early Minimization Therapy Kidney Transplantation</brief_title>
	<detailed_description />
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Calcineurin Inhibitors</mesh_term>
	<mesh_term>Alemtuzumab</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<criteria>Inclusion criterion : First deceaseddonor kidney transplantation Age &gt; 18 year Donor &lt; 65 year Cytomegalovirus ( CMV ) / EpsteinBarr virus ( EBV ) seropositivity panel reactive antibody ( PRA ) &lt; 10 % Written consent Exclusion criterion : Retransplantation , combine transplantation Prior immunosuppression le 6 month prior transplantation Induction therapy antibody Leukopenia &lt; 4000 , thrombocytopenia &lt; 100 000 , Haemoglobin &lt; 80 g/l History antithymoglobulin ( ATG ) anticluster differentiation 3 ( CD3 ) monoclonal antiTNFα Tuberculosis history Antihepatitis C virus ( HCV ) positivity , HBsAg HIV positivity Malignancy history Allergy study medication Fertile woman without contraception Pregnancy , breastfeed mother</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>